Avastin's breast cancer withdrawal (2008-2011)
The FDA granted accelerated approval to Genentech's Avastin for metastatic breast cancer in 2008 based on a trial showing it delayed tumor progression. The drug did not improve overall survival, and the FDA's oncology advisers voted 12-1 in 2010 to withdraw the indication. Genentech appealed; the agency's commissioner upheld the withdrawal in 2011.
Avastin came off the breast cancer label in November 2011.
The case became a reference point for the FDA's position that progression-free survival alone may not justify approval when overall survival data are available.
Ivonescimab targets VEGF, and the FDA applied similar logic: delaying progression did not outweigh the absence of a survival gain.
